Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Reexamination Certificate
2006-09-25
2009-11-10
Duffy, Patricia A (Department: 1645)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
C424S134100, C424S138100, C424S180100
Reexamination Certificate
active
07615225
ABSTRACT:
The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.
REFERENCES:
patent: 5519114 (1996-05-01), Johnson et al.
patent: 5545716 (1996-08-01), Johnson et al.
patent: 5728388 (1998-03-01), Terman
patent: 5858363 (1999-01-01), Dohlsten et al.
patent: 5859207 (1999-01-01), Johnson et al.
patent: 6042837 (2000-03-01), Kalland et al.
patent: 6126945 (2000-10-01), Terman et al.
patent: 6180097 (2001-01-01), Terman
patent: 6197299 (2001-03-01), Dohlsten et al.
patent: 6221351 (2001-04-01), Terman
patent: 6251385 (2001-06-01), Terman
patent: 6338845 (2002-01-01), Terman
patent: 6340461 (2002-01-01), Terman
patent: 6399332 (2002-06-01), Ulrich et al.
patent: 6447777 (2002-09-01), Terman et al.
patent: 6514498 (2003-02-01), Antonsson et al.
patent: 6632441 (2003-10-01), Schlievert et al.
patent: 6632640 (2003-10-01), Lee et al.
patent: 6692746 (2004-02-01), Terman et al.
patent: 6713284 (2004-03-01), Ulrich et al.
patent: 6962694 (2005-11-01), Soegaard et al.
patent: 7074909 (2006-07-01), Kingsman et al.
patent: 7189816 (2007-03-01), Brodin et al.
patent: 7226595 (2007-06-01), Antonsson et al.
patent: 7226601 (2007-06-01), Abrahmsen et al.
patent: 2001/0046501 (2001-11-01), Johnson et al.
patent: 2002/0018781 (2002-02-01), Schlievert et al.
patent: 2002/0028211 (2002-03-01), Kaempfer et al.
patent: 2002/0039585 (2002-04-01), Schlievert et al.
patent: 2002/0051765 (2002-05-01), Terman
patent: 2002/0058032 (2002-05-01), Hirai et al.
patent: 2002/0086813 (2002-07-01), Schlievert et al.
patent: 2002/0115190 (2002-08-01), Chen
patent: 2002/0141981 (2002-10-01), Lawman et al.
patent: 2002/0177551 (2002-11-01), Terman
patent: 2003/0009015 (2003-01-01), Ulrich et al.
patent: 2003/0036644 (2003-02-01), Ulrich
patent: 2003/0039655 (2003-02-01), Forsberg et al.
patent: 2003/0092894 (2003-05-01), Antonsson et al.
patent: 2003/0124142 (2003-07-01), Fraser et al.
patent: 2003/0157113 (2003-08-01), Terman
patent: 2004/0142464 (2004-07-01), Lawman et al.
patent: 2005/0226885 (2005-10-01), Soegaard et al.
patent: 2006/0057111 (2006-03-01), Hedlund et al.
patent: 2006/0062795 (2006-03-01), Abrahmsen et al.
patent: WO-96/01650 (1996-01-01), None
patent: WO-96/36366 (1996-11-01), None
patent: WO-97/36932 (1997-10-01), None
patent: WO-9736032 (1997-10-01), None
patent: WO-99/04820 (1999-02-01), None
patent: WO-01/30854 (2001-05-01), None
patent: WO-01/36486 (2001-05-01), None
Declaration from parent 4 pages.
Declaration from parent 31 pages.
Abrahamsen, L. et al., Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A; The EMBO Journal; 1995, v. 14, No. 13; pp. 2978-2786.
Alpaugh, R. K. et al., Superantigen-targeted Therapy: Phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies; Clinical Cancer Research 1998, Vo. 4 pp. 1903-1914.
Antonsson, P. et al. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR; J. Immuology; 1997; pp. 4245-4251.
Burks, E. et al., In vitro scanning saturation mutagenesis of an antibody binding pocket; Proc. Natl. Acad. Sci. USA, 1997. vol. 94, pp. 412-417.
Cavallin, A. et al., The spectral and thermodynamic properties of staphylococcal enterotoxin A, E, and variants suggest that structural modifications are important to control their function; J. Biol Chemistry; 2000; vol. 275, No. 3, pp. 1665-1672.
Dohlsten, M. et al., Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell based tumor therapy; Proc. Natl. Acad. Sci. USA 1994; vol. 91, pp. 8945-8949.
Forsberg et al., “Therapy of Human Non-small-cell lung Carcinoma Using Antibody Targeting of a Modified Superantigen,” British Journal of Cancer 85 (1), 2001, pp. 129-136.
Forsberg et al., “Therapy of Human Non-small-cell lung Carcinoma Using Antibody Targeting of a Modified Superantigen,” British Journal of Cancer 85 (1), 2001, pp. 129-136.
Griggs et al., “Mapping of Multiple Binding Domains of the Superantigen Staphylococcal Enterotoxin a for HLA,” Journal of Immunology vol. 148, 1992, pp. 2516-2521.
Griggs et al.,“Mapping of Multiple Binding Domains of the Superantigen Staphylococcal Enterotoxin a for HLA,” Journal of Immunology vol. 148, 1992, pp. 2516-2521.
Hakansson, M. et al., The Crystal Structure of Staphylococcal Enterotoxin H: Implications for Binding Properties to MHC Class II and TcR Molecules; J. Mol. Biol. 2000; 302, 527-537.
Hansson et al., “Genetically Engineered Superantigens as Tolerable Antitumor Agents,” Proc. Natl. Acad. Sci. vol. 94, Mar. 1997, pp. 2489-2494.
International Search Report for PCT/SE 02/01188.
Papageorgiou, A. Microbial superantigens: from structure to function; Trends in Microbiology, vol. 8, No. 8, pp. 369-375, 2000.
Preliminary Examination Report for PCT/SE 02/01188.
Rosendahl et al, “Long-Term Survival and Complete Cures of B16 Melanoma-Carrying Animals After Therapy with Tumor-Targeted IL-2 and Sea,” Int. J. Cancer 81, 1999, pp. 156-163.
Schad, E.M. et al., Crystal structure of the superantigen staphylococcal enterotoxin type A; The EMBO Journal vol. 14, No. 14, pp. 3292-3301, 1995.
Sogaard et al., “Antibody-targeted Superantigens in Cancer Immunotherapy,” Immunotechnology 2, 1996, pp. 151-162.
Sundstrom, M. et al. The co-crystal of staphylococcal enterotoxin type A with Zn.sup.2 at 2.7 .ANG.Resolution; The Journal of Biological Chemistry; vol. 271 No. 50, 1996 pp. 32212-32216.
Sundstrom, Michael et al. The crystal structure of staphylococcal enterotoxin type D reveals Zn.sup.2+-mediated homodimerization; The EMBO Journal vol. 15, No. 24, pp. 6832-6840, 1996.
Third Response to Written Opinion for PCT/SE 02/01188.
U.S. Appl. No. 09/463,470, filed Jan. 21, 2000.
Weinrauch, Y. Annual Review of Microbiology 53:155-87, 1999.
Antonsson Per
Erlandsson Eva
Forsberg Goran
Walse Bjorn
Active Biotech AB
Duffy Patricia A
Fulbright & Jaworski L.L.P.
LandOfFree
Methods for treating a subject having cancer by the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating a subject having cancer by the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating a subject having cancer by the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4082513